Andera Partners

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.